Ocedurenone
 | |
| Clinical data | |
|---|---|
| Other names | KBP-5074 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C28H30ClN5O2 |
| Molar mass | 504.03 g·mol−1 |
Ocedurenone, formerly known as KBP-5074,[1] is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments.[2][3] In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for up to USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.[4][5]
References
[edit]- ↑ "Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease". Nephrology. 16 March 2023. Retrieved 4 November 2023.
- ↑ Pitt, Bertram; Jaisser, Frederic; Bakris, George (October 2021). "An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension". Expert Opinion on Investigational Drugs. 30 (10): 1017–1023. doi:10.1080/13543784.2021.1985462. ISSN 1744-7658. PMID 34595995.
- ↑ Bakris, George; Pergola, Pablo E.; Delgado, Belkis; Genov, Diyan; Doliashvili, Tamar; Vo, Nam; Yang, Y. Fred; McCabe, James; Benn, Vincent; Pitt, Bertram (July 2021). "Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study". Hypertension. 78 (1): 74–81. doi:10.1161/HYPERTENSIONAHA.121.17073. PMC 8189259. PMID 33966452.
- ↑ "Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from Singapore Biotech". BioSpace. 16 October 2023. Retrieved 4 November 2023.
- ↑ "Novo Nordisk in $1.3 bln deal to buy hypertension drug". Reuters. 16 October 2023. Retrieved 4 November 2023.
 | This antihypertensive-related article is a stub. You can help Wikipedia by adding missing information. |